NBY - NovaBay reassures investors of liquidity level

Issuing a letter to investors, NovaBay Pharmaceuticals (NBY) said that the current liquidity level of the company would be sufficient to support its 2021 operations. The company shares are up ~12.0% in premarket.NovaBay focused on non-antibiotic anti-infective products also announced the upcoming launch of its consumer products Avenova® and CelleRx® Clinical Reset in brick-and-mortar retail stores.While Avenova will be available at CVS stores, CelleRx Clinical Reset will reach U.S. and Chinese consumers through select luxury retailers, the company said.As of Q3 2020, NovaBay’s cash and equivalents stood at $13.4M, ~94.2% higher than the level in 2019 year-end.

For further details see:

NovaBay reassures investors of liquidity level